Stock 42C IX BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

iX Biopharma Ltd. Stock

Equities

42C

SG1BD9000009

Pharmaceuticals

Market Closed - Singapore S.E.
Other stock markets
 03:14:38 2024-04-26 EDT 		5-day change 1st Jan Change
0.042 SGD +2.44% Intraday chart for iX Biopharma Ltd. +5.00% -6.67%
03-12 Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer MT
03-12 IX Biopharma Introduces New Sublingual Wafer MT

Financials

Sales 2022 14.39M 10.56M 14.44M Sales 2023 5.91M 4.34M 5.93M Capitalization 69.73M 51.18M 69.96M
Net income 2022 -4M -2.94M -4.01M Net income 2023 -9M -6.61M -9.03M EV / Sales 2022 7.87 x
Net cash position 2022 9.18M 6.74M 9.21M Net cash position 2023 2.2M 1.61M 2.2M EV / Sales 2023 11.4 x
P/E ratio 2022
-26.3 x
P/E ratio 2023
-7.22 x
Employees 45
Yield 2022 *
-
Yield 2023
-
Free-Float 49.01%
More Fundamentals * Assessed data

Chart iX Biopharma Ltd.

Dynamic Chart

Latest news about iX Biopharma Ltd.

Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer MT
IX Biopharma Introduces New Sublingual Wafer MT
IX Biopharma Ltd. Announces Development of Semaglutide Sublingual Wafer, Ixb 401, Targeting Diabetes and Obesity Markets CI
Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System MT
IX Biopharma Unveils Novel Drug Delivery System; Shares Surge 12% MT
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination MT
IX Biopharma Ltd. Unveils Novel NAD Wafers At the Centre for Healthy Longevity Conference 2024 CI
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9% MT
IX Biopharma Stays in Red in Fiscal H1 MT
IX Biopharma Ltd. Reports Earnings Results for the Half Year Ended December 31, 2023 CI
IX Biopharma Unit Ends Wafermine Licensing Deal with Seelos Therapeutics; Shares Tumble 10% MT
IX Biopharma Unit Launches Anti Ageing Products in US MT
IX Biopharma Ltd Announces its Wholly-Owned Subsidiary, Meltmed Inc, Introduces its New Suite of Fast-Dissolving Wafer Products in United States CI
Singapore Stocks Snap Losing Streak; Oxley Shares Slip 4% on Expected Losses in Fiscal H2, Fiscal 2023 MT
IX Biopharma Trims Losses in Fiscal H2; Shares Jump 17% MT
More news

Analyst Recommendations on iX Biopharma Ltd.

PhillipCapital Adjusts iX Biopharma’s Price Target to SG$0.25 From SG$0.355, Keeps at Buy MT
More recommendations

Press releases iX Biopharma Ltd.

IX Biopharma : Sustainability Report PU
General Announcement::CHANGES IN THE COMPOSITION OF THE BOARD AND BOARD COMMITTEES PU
General Announcement::Minutes of Annual General Meeting held on 15 October 2021 PU
General Announcement::iX Biopharma Expands Nutraceuticals Portfolio With Innovative Anti-Aging Sublingual NAD+ Product PU
General Announcement::iX Biopharma Signs Wafesil Licensing Agreement with China Resources Pharmaceutical Commercial Group PU
More press releases

News in other languages on iX Biopharma Ltd.

Acciones europeas cierran en máximos de más de un mes, apuntaladas por tecnológicas y cuidado de salud
More news

Quotes and Performance

1 day+2.44%
1 week+5.00%
Current month-19.23%
1 month-19.23%
3 months-2.33%
Current year-6.67%
More quotes

Highs and lows

1 week
0.03
Extreme 0.033
0.04
1 month
0.03
Extreme 0.033
0.06
Current year
0.03
Extreme 0.033
0.06
1 year
0.03
Extreme 0.033
0.10
3 years
0.03
Extreme 0.033
0.28
5 years
0.03
Extreme 0.033
0.35
10 years
0.03
Extreme 0.033
0.64
More quotes

Managers and Directors - iX Biopharma Ltd.

Managers TitleAgeSince
Yip Hang Lee CEO
 Chief Executive Officer - 04-05-07
Sien Lup Chew DFI
 Director of Finance/CFO 60 16-04-13
Janakan Krishnarajah COO
 Chief Operating Officer 45 16-03-31
Members of the board TitleAgeSince
Yip Hang Lee CEO
 Chief Executive Officer - 04-05-07
Shing Tung Ho BRD
 Director/Board Member 57 13-02-28
Patrick Davies BRD
 Director/Board Member 57 19-12-01
More insiders

Quotes

Date Price Change Volume
24-04-26 0.042 +2.44% 20,000
24-04-25 0.041 -4.65% 179,900
24-04-22 0.043 +7.50% 196,900
24-04-19 0.04 -11.11% 189,600

Delayed Quote Singapore S.E., April 26, 2024 at 03:14 am

More quotes

Company Profile

IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions. It has developed a patented drug delivery platform technology, WaferiX. WaferiX is a novel multi-drug delivery platform comprising a highly porous, amorphous and non-ionic matrix in a solid dosage form. The Company operates through two segments: Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and medicinal cannabis products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
Sector
Pharmaceuticals
Calendar
2024-08-18 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
IX BIOPHARMA LTD. Stock iX Biopharma Ltd.
-6.67% 23.68M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 42C Stock